21,051 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Lighthouse Financial LLC

Lighthouse Financial LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,051 shares of the company's stock, valued at approximately $1,811,000. Novo Nordisk A/S comprises approximately 1.5% of Lighthouse Financial LLC's holdings, making the stock its 19th biggest position.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL grew its holdings in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Transce3nd LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $39,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 1.3%

NYSE:NVO traded up $0.86 during trading hours on Thursday, hitting $69.46. 8,992,955 shares of the stock traded hands, compared to its average volume of 6,753,676. The firm has a 50 day moving average price of $65.74 and a 200 day moving average price of $82.29. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a market cap of $311.71 billion, a price-to-earnings ratio of 21.11, a PEG ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion for the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NVO. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Wall Street Zen upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.